Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC

On November 9, 2026 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, reported it will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer and FDA feedback supporting a clear Phase 3 path to potential accelerated approval in that patient population on Tuesday, November 10, 2026, at 7:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast information

The webcast can be accessed under "Events and Presentations" on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event for a limited time.

About Silevertinib

Silevertinib is an investigational oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC. It is also designed to potently inhibit key EGFR alterations seen in GBM, including EGFRvIII, while avoiding the paradoxical EGFR activation reported with reversible TKIs. To date, over 200 patients with EGFRm NSCLC or EGFR-altered GBM have been treated with silevertinib.

In addition to the ongoing Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, the Company is also conducting a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM (NCT07326566).

(Press release, Black Diamond Therapeutics, NOV 9, 2026, View Source [SID1234674504])

Oncovita Granted Orphan Drug Designation For MVdeltaC in Mesothelioma by the European Commission

On November 9, 2026 Oncovita, a French biotechnology company specialized in therapeutic and prophylactic vaccines, reported that the European Commission has granted orphan medicinal product designation to its lead investigational candidate, MVdeltaC, for the treatment of mesothelioma.
The decision, dated October 19, 2026, follows a positive opinion adopted on September 10, 2026, by the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP). It complements the U.S. Food and Drug Administration (FDA) orphan drug designation for MVdeltaC in pleural mesothelioma, announced in June 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A significant European regulatory milestone

European orphan designation involves an assessment of both the rare-disease criteria and the therapeutic context. Where satisfactory treatments are already authorised, sponsors must provide evidence supporting an assumption that their candidate could offer significant benefit to patients compared with existing methods.

"The European designation is an important milestone for MVdeltaC, particularly because the EU framework requires a substantiated rationale for potential significant benefit when treatments already exist," said Stéphane Altaba, CEO of Oncovita. "Together with the FDA designation obtained in 2025, it provides further encouragement for our development programme in mesothelioma. Our priority is now to advance our drug candidate into clinical development in late 2027 ".

A new immunotherapeutic approach for a challenging cancer

Mesothelioma is a rare and aggressive cancer. Its pleural form affects the membrane surrounding the lungs and is commonly associated with past asbestos exposure. Despite advances in treatment, substantial unmet needs remain, particularly for a majority of patients whose disease progresses with currently available therapies.
MVdeltaC is an investigational immuno-oncolytic therapy developed using Oncovita’s proprietary Measovir platform. It is based on the attenuated Schwarz strain of the measles vaccine virus, genetically modified to inactivate the viral C virulence factor.
The candidate is designed to combine direct lysis of tumour cells with activation of an anti-tumour immune response. Preclinical studies presented at the European Association for Cancer Research congress in June 2026 reported immunogenic tumour cell death, anti-tumour activity and immune memory in several experimental models of cancer, including mesothelioma models.

"Patients with pleural mesothelioma urgently need additional treatment options, particularly when their disease progresses despite existing therapies," said Professor Arnaud Scherpereel, a specialist in pneumology and thoracic oncology at Lille University Hospital. "MVdeltaC is a promising therapeutic approach, combining direct tumour cell killing with the potential to stimulate a broader anti-tumour immune response.The preclinical findings are encouraging and strengthen the rationale for bringing this innovative approach into clinical development. I believe MVdeltaC deserves to be investigated clinically for its potential to provide a meaningful new treatment option for patients with mesothelioma."

Clinical development planned for late 2027

Oncovita is preparing the transition of MVdeltaC into clinical development, including GMP/clinical-grade manufacturing. The company plans to initiate its first clinical trial in late 2027, subject to the required regulatory and ethics approvals.
The European and U.S. orphan designations provide access to incentives intended to support the development of treatments for rare diseases. In the EU, these include protocol assistance, potential reductions in regulatory fees and eligibility for ten years of market exclusivity following marketing authorisation, provided the applicable conditions are met.

(Press release, Oncovita, NOV 9, 2026, View Source [SID1234674520])

Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study

On November 9, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported that a patient with advanced liver cancer who participated in its completed Phase II study of Namodenoson has reached ten years of overall survival. The patient, whose complete response was previously reported by the Company, remains cancer-free and in good health.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This decade-long survival marks an exceptional individual outcome in advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Following the Company’s announcement of nine-year survival in November 2025, the patient’s continued well-being adds another year to this remarkable clinical story.

"Behind this ten-year milestone is a woman who continues to live well a decade after participating in our study with advanced liver cancer. For patients, families, and those of us working to develop new treatments, this is a deeply meaningful achievement," said Prof. Pnina Fishman, Chairperson and Chief Scientific Officer of Can-Fite. "Her exceptional outcome strengthens our commitment to advancing Namodenoson and evaluating its potential to provide durable clinical benefit for patients with liver cancer."

Namodenoson is currently being evaluated in Can-Fite’s ongoing randomized, double-blind, placebo-controlled pivotal Phase III study in patients with advanced HCC and underlying Child-Pugh B7 cirrhosis. As announced on September 2, 2026, overall survival across the pooled, blinded study population appeared longer than anticipated based on the study’s design assumptions, prompting the Company to evaluate earlier timing for the planned interim analysis. The study remains blinded, and the survival observation includes both Namodenoson- and placebo-treated patients; treatment-specific efficacy will be assessed through the planned analysis.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and is enrolling patients in a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.

(Press release, Can-Fite BioPharma, NOV 9, 2026, View Source [SID1234674465])

Nanobiotix to Participate in Investor Conferences in November

On November 9, 2026 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, reported that Company management will participate in the following investor conferences in November:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference in London
Date: Monday, November 16, 2026
Presentation Time: 8:30am ET / 1:30pm GMT
Location: London (UK)
Presenters: Laurent Levy, Chief Executive Officer and Arnd Christ, Chief Financial Officer

UBS Global Biopharma Conference
Date: Tuesday, November 17, 2026
Location: London (UK)

(Press release, Nanobiotix, NOV 9, 2026, View Source [SID1234674481])

PharmaLogic to Acquire Lantheus’ CDMO Business and Springfield, New Jersey Manufacturing Facility

On November 9, 2026 PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals, reported a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH). The financial terms of the transaction were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Springfield facility is a state-of-the-art radiopharmaceutical manufacturing site with a proven track record in theranostic manufacturing, research and clinical development. Its highly skilled team will join Agilera, PharmaLogic’s therapeutic CDMO franchise, upon completion of the transaction. The transaction also includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.

The acquisition expands PharmaLogic’s capacity to manufacture radiopharmaceutical therapeutics in the U.S. Agilera brings more than 15 years of experience supporting the development and commercial launch of radioligand therapies (RLTs) and currently supplies an alpha therapy to more than 30 countries. With the Springfield facility, PharmaLogic becomes the first therapeutic CDMO to offer a transatlantic platform, giving partners an end-to-end solution for RLTs, from early clinical development through commercial launch and global supply.

"This acquisition strengthens Agilera’s unique capabilities in radioligand therapies and expands our capacity in the U.S.," said Etienne Montagut, President and Chief Executive Officer of PharmaLogic. "We are proud to welcome the talented Springfield team, who will help us scale our operations to meet growing demand from our partners and the patients they serve."

"We have a long-standing relationship with PharmaLogic, which has been an important manufacturing partner for our PET products," said Mary Anne Heino, Executive Chairperson and Chief Executive Officer of Lantheus. "With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on this foundation while supporting reliable supply of our newly approved radiotherapeutic for patients and healthcare providers."

The transaction is subject to applicable regulatory review and the satisfaction of other customary closing conditions. The parties will continue to operate independently until the closing.

Advisors

Leerink Partners served as financial advisor to the Company, and Goodwin Procter LLP served as legal advisor.

Solomon Partners Securities LLC served as financial advisor to Lantheus, and Covington & Burling LLP served as legal advisor.

(Press release, Lantheus, NOV 9, 2026, View Source [SID1234674505])